Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease
2021 · Signal Transduction and Targeted Therapy · 57 citations
https://doi.org/10.1038/s41392-021-00628-x
H
Hao Liang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
40
Papers
1.1K
Citations
15
h-index
16
i10-index
Hao Liang is an academic researcher from Kunming University of Science and Technology. The author has contributed to research in topics: Computational Drug Discovery Methods & SARS-CoV-2 and COVID-19 Research & Pharmacogenetics and Drug Metabolism. The author has an h-index of 15, co-authored 34 publications.
ORCID: 0000-0003-4382-3704Papers by this author
worksSilybin A enhances circadian clock by targeting CRY1 and disrupting its interaction with CLOCK
2022 · Pharmacological Research - Modern Chinese Medicine · 8 citations
https://doi.org/10.1016/j.prmcm.2022.100159
Sequencing of the MHC region defines <i>HLA-DQA1</i> as the major independent risk for anti-citrullinated protein antibodies (ACPA)-positive rheumatoid arthritis in Han population
2018 · bioRxiv (Cold Spring Harbor Laboratory) · 0 citations
https://doi.org/10.1101/400937
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat